Lilly terminates Phase 1 atopic dermatitis trial; registers pediatric tirzepatide Phase 3
Eli Lilly posted results for a discontinued LY3844583 atopic dermatitis study and opened recruitment for a Phase 3 pediatric obesity trial of tirzepatide.
Eli Lilly and Company had one trial with newly posted results and one new Phase 3 study recruiting across multiple countries.
- LY3844583, a Phase 1 drug tested in healthy participants and in people with atopic dermatitis, was stopped early. The study was terminated due to a lack of efficacy signal in atopic dermatitis participants1, with results posted on 2026-10-13 and enrollment reaching 86 participants.
- Lilly's pediatric obesity program for tirzepatide (LY3298176) moved into recruiting status under a Phase 3 trial titled "ADVANCE-SURMOUNT-KIDS." The study is evaluating the drug in participants 6 to less than 12 years of age with obesity, as an addition to healthy lifestyle, under Master Protocol J4M-MC-PWMP2, with an estimated enrollment of 150 participants and a primary completion date targeted for December 2029.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.